BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 12432043)

  • 1. Cyclin E and survival in patients with breast cancer.
    Keyomarsi K; Tucker SL; Buchholz TA; Callister M; Ding Y; Hortobagyi GN; Bedrosian I; Knickerbocker C; Toyofuku W; Lowe M; Herliczek TW; Bacus SS
    N Engl J Med; 2002 Nov; 347(20):1566-75. PubMed ID: 12432043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
    Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle dysregulation influences survival in high risk breast cancer patients.
    Königsberg R; Rögelsperger O; Jäger W; Thalhammer T; Klimpfinger M; De Santis M; Hudec M; Dittrich C
    Cancer Invest; 2008 Aug; 26(7):734-40. PubMed ID: 18665474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of cyclin E expression in operable breast cancer.
    Potemski P; Kusińska R; Pasz-Walczak G; Piekarski JH; Watała C; Płuciennik E; Bednarek AK; Kordek R
    Med Sci Monit; 2009 Feb; 15(2):MT34-40. PubMed ID: 19179977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Voduc D; Nielsen TO; Cheang MC; Foulkes WD
    Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
    Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
    Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer.
    Zhou YJ; Xie YT; Gu J; Yan L; Guan GX; Liu X
    Eur J Surg Oncol; 2011 Dec; 37(12):1078-84. PubMed ID: 21944050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
    Mehdipour P; Pirouzpanah S; Sarafnejad A; Atri M; Shahrestani ST; Haidari M
    Cell Biol Int; 2009 Oct; 33(10):1050-6. PubMed ID: 19555767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
    Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
    Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer.
    Kim HK; Park IA; Heo DS; Noh DY; Choe KJ; Bang YJ; Kim NK
    Eur J Surg Oncol; 2001 Aug; 27(5):464-71. PubMed ID: 11504517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining.
    Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Jesionek-Kupnicka D; Pasz-Walczak G; Watala C; Kordek R
    Jpn J Clin Oncol; 2006 Mar; 36(3):142-9. PubMed ID: 16520356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer.
    Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
    J Surg Oncol; 2003 Aug; 83(4):241-7. PubMed ID: 12884237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
    Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.
    Peters MG; Vidal Mdel C; Giménez L; Mauro L; Armanasco E; Cresta C; Bal de Kier Joffé E; Puricelli L
    Oncol Rep; 2004 Nov; 12(5):1143-50. PubMed ID: 15492807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
    Kamai T; Takagi K; Asami H; Ito Y; Oshima H; Yoshida KI
    Br J Cancer; 2001 May; 84(9):1242-51. PubMed ID: 11336477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.